PUNE, India, October 10, 2016 /PRNewswire/ --
RnRMarketResearch.com adds "Alpha- Antitrypsin Deficiency - PipelineReview, H2 2016" market research report that provides an overview of its therapeutic pipeline with comprehensive information and comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration
Complete report on H2 2016 pipeline review of Alpha Antitrypsin Deficiency with 33 market data tables and 14 figures, spread across 108 pages is available at http://www.rnrmarketresearch.com/alpha-antitrypsin-deficiency-pipeline-review-h2-2016-market-report.html .
Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT), a protein that protects the lungs. Symptoms include shortness of breath and wheezing, lung infections, rapid heartbeat, weight loss and vision problems. Predisposing factors include smoking, exposure to dust, chemical fumes and infections.
The report 'Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Alpha- Antitrypsin Deficiency, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews of key players involved in therapeutic development for Alpha- Antitrypsin Deficiency and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 3, 2, 1, 10 and 3 respectively.
Companies discussed in this Alpha- Antitrypsin Deficiency Pipeline Review, H2 2016 report include Adverum Biotechnologies, Inc., Alnylam Pharmaceuticals, Inc., Applied Genetic Technologies Corporation, Arrowhead Pharmaceuticals, Inc., Carolus Therapeutics, Inc., Cevec Pharmaceuticals GmbH, Dicerna Pharmaceuticals, Inc., Digna Biotech, S.L., Editas Medicine, Inc., Grifols, S.A. , Inhibrx , Intellia Therapeutics, Inc., International Stem Cell Corporation, Ionis Pharmaceuticals, Inc., Kamada Ltd. , Polyphor Ltd. , ProMetic Life Sciences Inc., rEVO Biologics, Inc. and Sangamo BioSciences, Inc. Drug Profiles mentioned in this research report are ALN-AAT, alpha-1 proteinase inhibitor (human), alpha-1 proteinase inhibitor (human) second generation, ANN-001, ARC-AAT, CT-2009, DB-027, Drugs for Alpha-1 Antitrypsin Deficiency, Gene Therapy to Activate Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency, ISIS-AATRx, Oligonucleotides to Activate Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency, Oligonucleotides to Inhibit Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency, POL-6014, rAAV2-CB-hAAT, Recombinant A1PI, Recombinant Human Alpha-1 Antitrypsin, Recombinant Human Alpha-1 Antitrypsin Replacement for Alpha-Antitrypsin Deficiency, Recombinant Protein for Alpha-1 Antitrypsin Deficiency, RNAi Oligonucleotide for Alpha-1 Antitrypsin Deficiency and Liver Disease and Stem Cell Therapy for Alpha-Antitrypsin Deficiency and Crigler-Najjar Syndrome.
Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=708048 .
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Another newly published market research report titled on Bone Marrow Transplant Rejection - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Bone Marrow Transplant Rejection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplant Rejection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are AbbVie Inc, AbGenomics International, Inc., Actelion Ltd , Alexion Pharmaceuticals Inc, Amunix Operating Inc., Apceth GmbH & Co. KG, arGEN-X BV, Athersys, Inc., Bellicum Pharmaceuticals, Inc., Bio-Cancer Treatment International Limited, Biogen Inc, Boryung Pharmaceutical Co., Ltd., Bristol-Myers Squibb Company, Cantex Pharmaceuticals, Inc., Capricor Therapeutics, Inc., Cell Source, Inc., Cell2B S.A., CellECT Bio, Inc., Cleveland BioLabs, Inc., Compugen Ltd., Cynata Therapeutics Limited, Cytodyn Inc., Dompe Farmaceutici S.p.A., Dr. Falk Pharma GmbH, Escape Therapeutics, Inc., F. Hoffmann-La Roche Ltd., Fate Therapeutics, Inc., Generon (Shanghai) Corporation Ltd., Gilead Sciences, Inc. and GlaxoSmithKline Plc etc. Bone Marrow Transplant Rejection Pipeline market research report of 427 pages is available at http://www.rnrmarketresearch.com/bone-marrow-transplant-rejection-pipeline-review-h2-2016-market-report.html .
Explore more reports on Diseases & treatment.
RnRMarketResearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers.
Contact: Ritesh Tiwari 2nd floor, Metropole, Next to Inox theatre, Bund garden road, Pune-411001 Maharashtra, India. + 1 888 391 5441 firstname.lastname@example.org
SOURCE RnR Market Research
Subscribe to our Free Newsletters!
Malaria is a dangerous disease with lethal consequences that requires protective measures for ...
Merkel cell carcinoma is a rare and a highly aggressive primary skin cancer that grows rapidly and ...
Vitrectomy is a surgical procedure performed to remove a part or whole of the vitreous humor ...View All